Thromboprophylaxis in general medical patients

Baele, G; David, JL; De Maeseneer, M; Deneys, V; Dicato, MA; Gilis, L; Hainaut, P; Hermans, C; Jochmans, K; Motte, S; Van der Plancken, M; Verhaeghe, Raymond; Vermylen, Jozef; Von Kemp, K; Wautrecht, JC; Zicot, M

doi:10.1179/acb.2002.061

Thromboprophylaxis in general medical patients

Author:

Baele, G

David, JL ; De Maeseneer, M ; Deneys, V ; Dicato, MA ; Gilis, L ; Hainaut, P ; Hermans, C ; Jochmans, K ; Motte, S ; Van der Plancken, M ; Verhaeghe, Raymond ; Vermylen, Jozef ; Von Kemp, K ; Wautrecht, JC ; Zicot, M

Keywords:

molecular-weight heparin, venous thromboembolism, prevention, enoxaparin, inpatients, prophylaxis, bedridden, trial, risk, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, MOLECULAR-WEIGHT HEPARIN, VENOUS THROMBOEMBOLISM, PREVENTION, ENOXAPARIN, INPATIENTS, PROPHYLAXIS, BEDRIDDEN, TRIAL, RISK, Hospitalization, Humans, Pulmonary Embolism, Risk Factors, Venous Thrombosis, Thrombosis Guidelines Group of the Belgian Society on Thrombosis and Haemostasis and the Belgian Working Group on Angiology, 1101 Medical Biochemistry and Metabolomics, 3202 Clinical sciences